Literature DB >> 8957041

Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy.

E Coroneos1, G Petrusevska, F Varghese, L D Truong.   

Abstract

Both alpha- and beta- interferons (IFNs) have been increasingly used for the treatment of many types of malignancy, and recently the use of alpha-IFN in the management of hepatitis C virus (HCV) infection with or without renal involvement has been emphasized. We report a patient who developed nephrotic syndrome and acute renal failure while being treated with alpha-IFN for HCV infection. The renal biopsy showed focal segmental glomerulosclerosis and tubulointerstitial nephritis. Although several renal lesions have been described in association with either alpha-IFN treatment or HCV infection, focal segmental glomerulosclerosis has not been emphasized in either instance. This case also indicates that when renal abnormalities occur during treatment of HCV infection with alpha-IFN, kidney biopsy may define the responsible renal lesions, suggest possible association with other conditions, and serve as a guideline for proper management.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957041     DOI: 10.1016/s0272-6386(96)90389-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C.

Authors:  D F Stein; A Ahmed; V Sunkhara; W Khalbuss
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

2.  Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.

Authors:  Ajit Sood; Vandana Midha; Jaswinder S Sandhu; Neena Sood; Amarjit Kaur; Rasham Mittal; Sandeep Puri
Journal:  Indian J Gastroenterol       Date:  2010-06

Review 3.  Interferon alpha sensitisation induced fatal renal insufficiency in a patient with chronic myeloid leukaemia: case report and review of literature.

Authors:  M Colovic; V Jurisic; G Jankovic; D Jovanovic; L J Nikolic; J Dimitrijevic
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

4.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

5.  Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection.

Authors:  Sriraj Kanungo; Srinath Tamirisa; Rajalakshmi Gopalakrishnan; Luis Salinas-Madrigal; Bahar Bastani
Journal:  Int Urol Nephrol       Date:  2009-06-04       Impact factor: 2.370

6.  An unexpected presentation: minimal change disease in an adult with treatment-naïve hepatitis C.

Authors:  Audrey L Stokes; Tarek Alhamad; Catherine S Abendroth; Hosam A Farag; Navin Verma
Journal:  Int Urol Nephrol       Date:  2012-09-22       Impact factor: 2.370

Review 7.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

Review 8.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

9.  Collapsing glomerulopathy after hepatitis C pegylated interferon treatment. Recovery of renal function with high-dose steroid treatment.

Authors:  Roberto H Berdichevski; Eduardo M De Carvalho; Maria Isabel Edelweiss; Luiz Felipe Gonçalves; Roberto C Manfro
Journal:  NDT Plus       Date:  2010-08-24

10.  Plasmacytoid dendritic cells promote acute kidney injury by producing interferon-α.

Authors:  Bo Deng; Yuli Lin; Yusheng Chen; Shuai Ma; Qian Cai; Wenji Wang; Bingji Li; Tingyan Liu; Peihui Zhou; Rui He; Feng Ding
Journal:  Cell Mol Immunol       Date:  2020-01-03       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.